{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Palandri F"],"funding":["Ministero della Salute"],"pagination":["e70320"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904337"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["132(4)"],"pubmed_abstract":["<h4>Background</h4>Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib.<h4>Methods</h4>The RUX-MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment-emergent cytopenia, persistent cytopenia, and improved anemia.<h4>Results</h4>At baseline, 40.6% of patients presented with cytopenia, increasing to 57.8% after 6 months. Baseline cytopenia was associated with significantly reduced median overall survival (OS) compared to noncytopenic patients (3.7 vs. 6.7 years). Prognosis varied notably across groups: patients who remained noncytopenic had the median best OS (8.1 years), whereas those with persi"],"journal":["Cancer"],"pubmed_title":["Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis."],"pmcid":["PMC12904337"],"funding_grant_id":["RC-2025-2797275"],"pubmed_authors":["Pugliese N","Bonifacio M","Crugnola M","Scalzulli E","Cilloni D","Duminuco A","Heidel FH","Benevolo G","Martino B","Iurlo A","Isidori A","Breccia M","Palandri F","Bosi C","Beggiato E","Lemoli RM","Branzanti F","Dedola A","Morsia E","Binotto G","Tieghi A","Farina M","Pane F","Abruzzese E","Caocci G","Bocchia M","Sartor C","Palumbo GA","Cavazzini F","Tiribelli M","Cattaneo D","Elli EM"],"additional_accession":[]},"is_claimable":false,"name":"Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.","description":"<h4>Background</h4>Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib.<h4>Methods</h4>The RUX-MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment-emergent cytopenia, persistent cytopenia, and improved anemia.<h4>Results</h4>At baseline, 40.6% of patients presented with cytopenia, increasing to 57.8% after 6 months. Baseline cytopenia was associated with significantly reduced median overall survival (OS) compared to noncytopenic patients (3.7 vs. 6.7 years). Prognosis varied notably across groups: patients who remained noncytopenic had the median best OS (8.1 years), whereas those with persi","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T21:59:42.674Z","creation":"2026-07-09T10:19:56.156Z"},"accession":"S-EPMC12904337","cross_references":{"pubmed":["41686528"],"doi":["10.1002/cncr.70320"]}}